Amyris, Inc. (NASDAQ:AMRS) shares hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $2.61 and last traded at $2.60, with a volume of 574,293 shares trading hands. The stock had previously closed at $2.78.

AMRS has been the topic of several recent analyst reports. Zacks Investment Research raised Amyris from a “sell” rating to a “hold” rating in a research report on Tuesday. ValuEngine lowered Amyris from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Amyris in a research report on Tuesday, May 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $31.13.

The stock’s market cap is $50.11 million. The firm’s 50-day moving average price is $3.52 and its 200 day moving average price is $6.09.

Amyris (NASDAQ:AMRS) last announced its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($1.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by $0.60. The company had revenue of $13 million during the quarter, compared to analysts’ expectations of $32.30 million. During the same period in the prior year, the company posted ($2.55) EPS. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. On average, equities research analysts anticipate that Amyris, Inc. will post ($3.98) EPS for the current fiscal year.

In related news, Director Patrick Y. Yang purchased 300,000 shares of the stock in a transaction that occurred on Friday, May 19th. The stock was purchased at an average cost of $0.29 per share, for a total transaction of $87,000.00. Following the acquisition, the director now owns 153,000 shares in the company, valued at $44,370. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.30% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in Amyris stock. Carl Domino Inc raised its stake in shares of Amyris, Inc. (NASDAQ:AMRS) by 37.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 201,925 shares of the biotechnology company’s stock after buying an additional 54,925 shares during the period. Carl Domino Inc owned 0.07% of Amyris worth $107,000 as of its most recent SEC filing.

WARNING: “Amyris, Inc. (NASDAQ:AMRS) Hits New 12-Month Low at $2.61” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with's FREE daily email newsletter.